CY2228B1 - Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens - Google Patents

Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens

Info

Publication number
CY2228B1
CY2228B1 CY0100017A CY0100017A CY2228B1 CY 2228 B1 CY2228 B1 CY 2228B1 CY 0100017 A CY0100017 A CY 0100017A CY 0100017 A CY0100017 A CY 0100017A CY 2228 B1 CY2228 B1 CY 2228B1
Authority
CY
Cyprus
Prior art keywords
establishment
therapeutic regimens
estrogen secretion
extended therapeutic
ovarian estrogen
Prior art date
Application number
CY0100017A
Other languages
English (en)
Inventor
Gary D Hodgen
Audrey Philips
Original Assignee
Hampton Roads Medical College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26959766&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2228(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/467,860 external-priority patent/US5658884A/en
Application filed by Hampton Roads Medical College filed Critical Hampton Roads Medical College
Publication of CY2228B1 publication Critical patent/CY2228B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CY0100017A 1994-07-22 2001-07-26 Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens CY2228B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27959394A 1994-07-22 1994-07-22
US08/467,860 US5658884A (en) 1994-07-22 1995-06-06 Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens

Publications (1)

Publication Number Publication Date
CY2228B1 true CY2228B1 (en) 2003-04-18

Family

ID=26959766

Family Applications (1)

Application Number Title Priority Date Filing Date
CY0100017A CY2228B1 (en) 1994-07-22 2001-07-26 Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens

Country Status (29)

Country Link
EP (1) EP0769956B1 (es)
JP (1) JP3138477B2 (es)
CN (1) CN1137722C (es)
AP (1) AP775A (es)
AT (1) ATE190494T1 (es)
AU (1) AU691952B2 (es)
BG (1) BG63363B1 (es)
BR (1) BR9508718A (es)
CA (1) CA2195745C (es)
CY (1) CY2228B1 (es)
CZ (1) CZ291803B6 (es)
DE (1) DE69515666T2 (es)
DK (1) DK0769956T3 (es)
EE (1) EE03515B1 (es)
ES (1) ES2145286T3 (es)
FI (1) FI970244A (es)
GR (1) GR3033590T3 (es)
HU (1) HU218910B (es)
IL (1) IL114655A (es)
IS (1) IS4413A (es)
LV (1) LV11823B (es)
MX (1) MX9700574A (es)
NO (1) NO970257L (es)
NZ (1) NZ290554A (es)
OA (1) OA10730A (es)
PT (1) PT769956E (es)
RU (1) RU2181598C2 (es)
SK (1) SK282118B6 (es)
WO (1) WO1996003138A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173592B1 (en) 1999-03-31 2012-05-08 Zentaris Ivf Gmbh Method for a programmed controlled ovarian stimulation protocol
UA73956C2 (en) * 1999-09-23 2005-10-17 Zentaris Gmbh Method for therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction due to extrauterine proliferation of endometrial tissue
DE10137174A1 (de) * 2001-07-31 2003-02-13 Zentaris Ag Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität
GB0616111D0 (en) * 2006-06-16 2006-09-20 Ardana Bioscience Ltd Agents, methods and uses
EP2095818A1 (en) 2008-02-29 2009-09-02 AEterna Zentaris GmbH Use of LHRH antagonists at non-castrating doses
EP2307040B1 (en) * 2008-05-29 2015-09-09 Isr Immune System Regulation Ab Use of gnrh and sex hormones for treating viral disease, in particular hiv/aids
ES2753539T3 (es) * 2015-05-18 2020-04-13 Nerre Therapeutics Ltd Antagonista del receptor NK-1/NK-3 para el tratamiento de los sofocos
EP3560555A1 (en) * 2018-04-26 2019-10-30 LifeArc A composition for treating one or more estrogen related diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171835A (en) * 1988-10-21 1992-12-15 The Administrators Of The Tulane Educational Fund LHRH antagonists
US5169932A (en) * 1989-10-30 1992-12-08 The Salk Institute For Biological Studies Gnrh analogs
US5211952A (en) * 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
ZA924811B (en) * 1991-06-28 1993-12-29 Endorecherche Inc Controlled release systems and low dose androgens
US5681817A (en) * 1994-02-04 1997-10-28 The Medical College Of Hampton Roads Treatment of ovarian estrogen dependent conditions
US5407955A (en) * 1994-02-18 1995-04-18 Eli Lilly And Company Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease

Also Published As

Publication number Publication date
CZ291803B6 (cs) 2003-06-18
CN1200674A (zh) 1998-12-02
IL114655A (en) 2005-08-31
CA2195745C (en) 2005-03-29
OA10730A (en) 2001-06-07
JPH10503203A (ja) 1998-03-24
BR9508718A (pt) 1997-12-30
MX9700574A (es) 1997-12-31
HUT77127A (hu) 1998-03-02
WO1996003138A1 (en) 1996-02-08
HU9700046D0 (en) 1997-02-28
FI970244A0 (fi) 1997-01-21
CN1137722C (zh) 2004-02-11
AP9700913A0 (en) 1997-01-31
ES2145286T3 (es) 2000-07-01
EP0769956B1 (en) 2000-03-15
FI970244A (fi) 1997-01-21
DK0769956T3 (da) 2000-06-05
RU2181598C2 (ru) 2002-04-27
LV11823A (lv) 1997-08-20
IL114655A0 (en) 1995-11-27
DE69515666D1 (de) 2000-04-20
EP0769956A4 (en) 1999-03-10
GR3033590T3 (en) 2000-09-29
ATE190494T1 (de) 2000-04-15
JP3138477B2 (ja) 2001-02-26
BG63363B1 (bg) 2001-11-30
AU3132095A (en) 1996-02-22
PT769956E (pt) 2000-07-31
IS4413A (is) 1997-01-14
EE9700208A (et) 1998-02-16
BG101158A (en) 1997-09-30
SK7097A3 (en) 1997-11-05
EE03515B1 (et) 2001-10-15
AP775A (en) 1999-10-28
LV11823B (en) 1998-03-20
NZ290554A (en) 2000-08-25
NO970257D0 (no) 1997-01-21
HU218910B (hu) 2000-12-28
EP0769956A1 (en) 1997-05-02
AU691952B2 (en) 1998-05-28
DE69515666T2 (de) 2000-07-06
NO970257L (no) 1997-01-21
CA2195745A1 (en) 1996-02-08
SK282118B6 (sk) 2001-11-06
CZ15097A3 (en) 1997-11-12

Similar Documents

Publication Publication Date Title
AP9600840A0 (en) Treatment of ovarian estrogen dependent conditions
GB2314737B (en) Method of enabling handoff
PL311736A1 (en) Derivatives of 1h-imidazoles
IL138129A0 (en) Therapy of estrogen associated disorders
IL135232A (en) 21-hydroxy-6 19-oxidoprogesterone for treating excess of glucocorticoids
GB9512290D0 (en) Uses of polyhexanide
HU9700046D0 (en) Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens
PL312692A1 (en) New derivatives of dialkoxy-pyridinol-benzimidazole
LT97021A (en) Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens
SG64482A1 (en) Controlling apparatus of escalator
IL127281A0 (en) Novel devices for transdermal administering of trimegestone
IL130209A (en) Therapeutic application of a thienylcylohexylamine derivatives
ZA95694B (en) Novel derivatives of tetramethylcyclopropane
GB9617264D0 (en) Improvements relating to means of controlling different apparatus
PL310119A1 (en) Double-arm sail boom of adjustable length for windsurfboards
ZA983631B (en) Sulfatation of estrogen mixtures
GB2294391B (en) Screen for personal shower
KR0122183Y1 (en) Apparatus for controlling ring of telephone
NZ328739A (en) Treatment of estrogen therapy using 8,9-dehydroesterone
TW356985U (en) Automatically hanging-up apparatus of main phone as the extension is lifting-up
IL108544A0 (en) Heterocyclic steroidal anti-cancer agents
TW310593U (en) Improved folding structure of walk-assisting apparatus
GB9414192D0 (en) Synthesis of 17-(3-pyridyl) steroids
TW452155U (en) Improved transformer structure of charging machine
TW356826U (en) Improved structure for wind-blade set of drawnwork machine